Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Cancer Research|
|State||Published - Mar 15 2009|
ASJC Scopus subject areas
- Cancer Research